Research and development expense in fiscal Q3 2025 -- $4.5 million versus $4.9 million in fiscal Q3 2024. Net loss -- $5.9 ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...